1. Home
  2. FIVN vs HRMY Comparison

FIVN vs HRMY Comparison

Compare FIVN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five9 Inc.

FIVN

Five9 Inc.

HOLD

Current Price

$27.04

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$35.77

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIVN
HRMY
Founded
2001
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.2B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
FIVN
HRMY
Price
$27.04
$35.77
Analyst Decision
Buy
Buy
Analyst Count
18
9
Target Price
$26.06
$44.11
AVG Volume (30 Days)
2.2M
856.6K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
364.71
7.97
EPS
0.21
0.55
Revenue
$1,149,088,000.00
$868,453,000.00
Revenue This Year
$11.39
$19.75
Revenue Next Year
$10.00
$12.88
P/E Ratio
$121.67
$65.47
Revenue Growth
10.28
21.51
52 Week Low
$13.29
$25.52
52 Week High
$28.51
$40.87

Technical Indicators

Market Signals
Indicator
FIVN
HRMY
Relative Strength Index (RSI) 62.95 52.97
Support Level $17.66 $35.05
Resistance Level N/A $39.07
Average True Range (ATR) 1.64 1.61
MACD -0.01 -0.10
Stochastic Oscillator 94.22 56.24

Price Performance

Historical Comparison
FIVN
HRMY

About FIVN Five9 Inc.

Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: